Annual Drug Patent Expirations for OFEV
Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for OFEV.
This drug has two hundred and fourteen patent family members in fifty-one countries.
The generic ingredient in OFEV is nintedanib esylate. One supplier is listed for this compound. Additional details are available on the nintedanib esylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
